Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease
NCT02238145 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 660
Last updated 2014-09-12
Summary
To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Atrovent® Inhaletten
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-01-31
- Primary Completion
- 1999-11-30
More Related Trials
-
Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
NCT02238158 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02238184 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
NCT02233920 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02232594 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
NCT02231424 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
NCT02233907 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02244216 ·Status: COMPLETED
-
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236169 ·Status: COMPLETED ·Phase: PHASE2
-
Actuation Indicator Trial in Patients With COPD
NCT00928746 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
NCT02260011 ·Status: COMPLETED ·Phase: PHASE2
-
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01350128 ·Status: COMPLETED ·Phase: PHASE2
-
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
NCT02552160 ·Status: COMPLETED
-
Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease
NCT02231437 ·Status: COMPLETED
-
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
NCT02937584 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00911651 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172469 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
NCT02743013 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00274092 ·Status: COMPLETED ·Phase: PHASE3
-
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
NCT02573155 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Patients With COPD
NCT00215384 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
NCT02359292 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
NCT04078126 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease
NCT02177344 ·Status: COMPLETED ·Phase: PHASE3
-
A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients
NCT01498081 ·Status: COMPLETED ·Phase: PHASE2